| Company | Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
GlaxoSmithKline plc
| LON
|
GSK
|
1,666.00
|
|
+1.00
(0.06%)
| 81,976.95M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
GlaxoSmithKline plc (ADR)
| NYSE
|
GSK
|
51.48
|
|
-0.99
(-1.89%)
| 126,372.98M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
IPG Investment Partners Group AG
| ETR
|
GSK
|
0.0000
|
|
|
|
|
|
IPG Investment Partners Group AG, formerly known as IPG Investment Partners
Group Wertpapierhandelsbank AG, is a Germany-based investment bank for ...
| |
| |
|
|
GlaxoSmithKline PLC
| FRA
|
GS7
|
19.62
|
|
0.00
(0.00%)
|
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
Cyclacel Pharmaceuticals Inc
| NASDAQ
|
CYCC
|
3.09
|
|
-0.03
(-0.96%)
| 26.06M
|
|
|
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the
immune system to treat cancer and other serious illnesses.
| |
| |
|
|
Cytokinetics, Inc.
| NASDAQ
|
CYTK
|
1.82
|
|
-0.07
(-3.70%)
| 266.56M
|
|
|
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused
on the discovery and development of small molecule therapeutics that ...
| |
| |
|
|
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
| NASDAQ
|
CYCCP
|
7.50
|
|
0.00
(0.00%)
| 3.16M
|
|
|
|
|
|
CYCLACEL PHARM. DL-,001
| FRA
|
UXI2
|
2.28
|
|
0.00
(0.00%)
|
|
|
|
|
|
|
CYTOKINETICS INC. DL-,001
| FRA
|
KK3
|
1.44
|
|
0.00
(0.00%)
|
|
|
|
|
|
